MX2009009243A - Administracion oral de una calcitonina. - Google Patents
Administracion oral de una calcitonina.Info
- Publication number
- MX2009009243A MX2009009243A MX2009009243A MX2009009243A MX2009009243A MX 2009009243 A MX2009009243 A MX 2009009243A MX 2009009243 A MX2009009243 A MX 2009009243A MX 2009009243 A MX2009009243 A MX 2009009243A MX 2009009243 A MX2009009243 A MX 2009009243A
- Authority
- MX
- Mexico
- Prior art keywords
- calcitonin
- peptide drugs
- oral administration
- oral
- bioavailability
- Prior art date
Links
- 102000055006 Calcitonin Human genes 0.000 title abstract 5
- 108060001064 Calcitonin Proteins 0.000 title abstract 5
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title abstract 5
- 229960004015 calcitonin Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 229940124447 delivery agent Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
La invención se refiere a un método para administrar composiciones farmacéuticas que comprenden fármacos peptídicos, tales como una calcitonina, en combinación con uno o más agentes de suministro oral, junto con una cantidad de un líquido, y a un método para el tratamiento de los trastornos que respondan a la acción de los fármacos peptídicos, tales como una calcitonina, empleando este método de administración, para mejorar la biodisponibilidad oral de una calcitonina. Los métodos de la invención aumentan la absorción oral y la biodisponibilidad sistémica de los fármacos peptídicos, tales como una calcitonina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89259407P | 2007-03-02 | 2007-03-02 | |
| PCT/US2008/055399 WO2008109385A2 (en) | 2007-03-02 | 2008-02-29 | Oral administration of a calcitonin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009009243A true MX2009009243A (es) | 2009-09-08 |
Family
ID=39496395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009009243A MX2009009243A (es) | 2007-03-02 | 2008-02-29 | Administracion oral de una calcitonina. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8410052B2 (es) |
| EP (1) | EP2131810B1 (es) |
| JP (1) | JP5249246B2 (es) |
| KR (2) | KR20150091536A (es) |
| CN (2) | CN101621991A (es) |
| AT (1) | ATE507818T1 (es) |
| AU (1) | AU2008223108B2 (es) |
| BR (1) | BRPI0808517A2 (es) |
| CA (1) | CA2679782C (es) |
| DE (1) | DE602008006700D1 (es) |
| ES (1) | ES2365648T3 (es) |
| MX (1) | MX2009009243A (es) |
| PL (1) | PL2131810T3 (es) |
| PT (1) | PT2131810E (es) |
| RU (2) | RU2009136303A (es) |
| WO (1) | WO2008109385A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60321B1 (sr) | 2010-12-16 | 2020-07-31 | Novo Nordisk As | Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline |
| RU2602601C2 (ru) | 2011-04-12 | 2016-11-20 | Ново Нордиск А/С | Дважды ацилированные производные glp-1 |
| EA201490676A1 (ru) * | 2011-09-22 | 2015-02-27 | Экселиксис, Инк. | Способ лечения остеопороза |
| CN111494323B (zh) | 2012-03-22 | 2023-03-28 | 诺和诺德股份有限公司 | 包含递送剂的组合物及其制备 |
| LT2827885T (lt) | 2012-03-22 | 2018-10-10 | Novo Nordisk A/S | Glp-1 peptidų kompozicijos ir jų gavimas |
| DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
| ES2871328T3 (es) | 2012-06-20 | 2021-10-28 | Novo Nordisk As | Formulación de comprimido que comprende un péptido y un agente de suministro |
| RU2671406C2 (ru) | 2013-05-02 | 2018-10-31 | Ново Нордиск А/С | Пероральная дозированная форма соединений глюкагоноподобного пептида-1 |
| CN104961687B (zh) * | 2015-06-03 | 2017-07-25 | 苏州维泰生物技术有限公司 | 1,2‑二嗪衍生物及其制剂、用途 |
| HUE063787T2 (hu) | 2018-02-02 | 2024-01-28 | Novo Nordisk As | Egy GLP-1 agonistát, egy N-(8-(2-hidroxibenzoil)amino) kaprilsav sót és egy síkosítóanyagot tartalmazó szilárd készítmények |
| CA3180660A1 (en) * | 2020-04-22 | 2021-10-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Bioactive phenolate ionic complexes |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| WO2000059480A1 (en) | 1999-04-05 | 2000-10-12 | Emisphere Technologies, Inc. | Lyophilized solid dosage forms and methods of making |
| CA2369591C (en) | 1999-04-05 | 2011-06-14 | Emisphere Technologies, Inc. | Disodium salts, monohydrate, and ethanol solvates |
| US7049283B2 (en) | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| WO2003015822A1 (en) | 2001-08-17 | 2003-02-27 | Novartis Ag | 5-cnac as oral delivery agent for parathyroid hormone fragments |
| US20050054557A1 (en) | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| TWI307279B (en) | 2002-08-01 | 2009-03-11 | Novartis Ag | Oral administration of calcitonin |
| WO2005014031A1 (en) * | 2003-07-23 | 2005-02-17 | Novartis Ag | Use of calcitonin in osteoarthritis |
-
2008
- 2008-02-29 JP JP2009551864A patent/JP5249246B2/ja not_active Expired - Fee Related
- 2008-02-29 CN CN200880006790A patent/CN101621991A/zh active Pending
- 2008-02-29 ES ES08743617T patent/ES2365648T3/es active Active
- 2008-02-29 PT PT08743617T patent/PT2131810E/pt unknown
- 2008-02-29 DE DE602008006700T patent/DE602008006700D1/de active Active
- 2008-02-29 WO PCT/US2008/055399 patent/WO2008109385A2/en not_active Ceased
- 2008-02-29 AU AU2008223108A patent/AU2008223108B2/en not_active Ceased
- 2008-02-29 AT AT08743617T patent/ATE507818T1/de active
- 2008-02-29 US US12/529,371 patent/US8410052B2/en not_active Expired - Fee Related
- 2008-02-29 PL PL08743617T patent/PL2131810T3/pl unknown
- 2008-02-29 KR KR1020157020307A patent/KR20150091536A/ko not_active Ceased
- 2008-02-29 CN CN201710436918.4A patent/CN107050433A/zh active Pending
- 2008-02-29 CA CA2679782A patent/CA2679782C/en not_active Expired - Fee Related
- 2008-02-29 MX MX2009009243A patent/MX2009009243A/es active IP Right Grant
- 2008-02-29 BR BRPI0808517-0A patent/BRPI0808517A2/pt not_active IP Right Cessation
- 2008-02-29 RU RU2009136303/15A patent/RU2009136303A/ru unknown
- 2008-02-29 EP EP08743617A patent/EP2131810B1/en not_active Not-in-force
- 2008-02-29 KR KR1020097018236A patent/KR101564114B1/ko not_active Expired - Fee Related
-
2013
- 2013-11-13 RU RU2013150659/15A patent/RU2013150659A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL2131810T3 (pl) | 2011-09-30 |
| US20100210526A1 (en) | 2010-08-19 |
| KR20090116772A (ko) | 2009-11-11 |
| EP2131810B1 (en) | 2011-05-04 |
| ES2365648T3 (es) | 2011-10-07 |
| RU2013150659A (ru) | 2015-05-20 |
| DE602008006700D1 (es) | 2011-06-16 |
| JP2010520221A (ja) | 2010-06-10 |
| AU2008223108A2 (en) | 2009-09-10 |
| CN107050433A (zh) | 2017-08-18 |
| CN101621991A (zh) | 2010-01-06 |
| US8410052B2 (en) | 2013-04-02 |
| EP2131810A2 (en) | 2009-12-16 |
| JP5249246B2 (ja) | 2013-07-31 |
| WO2008109385A3 (en) | 2009-04-09 |
| CA2679782A1 (en) | 2008-09-12 |
| AU2008223108B2 (en) | 2013-10-10 |
| AU2008223108A1 (en) | 2008-09-12 |
| ATE507818T1 (de) | 2011-05-15 |
| KR20150091536A (ko) | 2015-08-11 |
| CA2679782C (en) | 2015-02-17 |
| KR101564114B1 (ko) | 2015-10-28 |
| PT2131810E (pt) | 2011-08-03 |
| WO2008109385A2 (en) | 2008-09-12 |
| RU2009136303A (ru) | 2011-04-10 |
| BRPI0808517A2 (pt) | 2014-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602008006700D1 (es) | ||
| UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
| WO2008085765A3 (en) | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | |
| WO2010029441A3 (en) | Nasal delivery | |
| MX2009002314A (es) | Composiciones farmaceuticas que comprenden hgh para suministro oral. | |
| BR112013022044A2 (pt) | veículo mastigável para absorção na boca | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
| DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
| UA99431C2 (uk) | Спосіб збирання пристрою для доставки ліків та пристрій для доставки ліків | |
| WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
| WO2011141685A3 (fr) | Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants | |
| MY153408A (en) | Novel methods | |
| EE05761B1 (et) | Kombineeritud ravimkoostis diabeedi ning ainevahetushäirete raviks | |
| IL196425A0 (en) | Pharmaceutical compositions containing ibuprofen and famotidine | |
| MX353649B (es) | Proteinas protozoarias variables de superficie (vsp) como vehiculos para la administracion de farmacos. | |
| WO2006138608A3 (en) | Pharmaceutical compositions and use thereof | |
| EA200702522A1 (ru) | Система доставки лекарств в полость рта и способы ее применения | |
| BR112015014095A2 (pt) | entrega transmucosal de acetato de glatirâmero | |
| DK1883387T3 (da) | Beholder til flydende medikamenter, der skal administreres | |
| MY149863A (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
| WO2009019307A3 (en) | Oral calcitonin compositions and applications thereof | |
| TW200509985A (en) | Drug delivery system for sub-Tenon administration of fine particles | |
| MX2010013484A (es) | Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |